Literature DB >> 7843429

Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome.

M P Goldsman1, A Pedram, C E Dominguez, I Ciuffardi, E Levin, R H Asch.   

Abstract

OBJECTIVE: To examine the effect of follicular fluid (FF) and peritoneal fluid (PF) from patients undergoing assisted reproductive technology procedures on endothelial barrier function. This was determined in vitro by measuring the permeability of filter-grown bovine aortic endothelial cell monolayers to a permeability marker.
DESIGN: Endothelial cells obtained from bovine thoracic arotas were treated with collagenase solution and plated on millicell filters, on which they formed confluent monolayers. Flux rate was determined at 60 minutes by measuring the radioactive tracer (3H mannitol) permeating from the apical to the basolateral part of the filter. Fifty-eight samples of FF and PF, both from stimulated and natural cycles were analyzed and grouped according to the number of eggs retrieved. Follicular fluid and PF samples from natural cycles were used as controls.
RESULTS: There was an augmentation in the permeability rate of both FF and PF from patients undergoing controlled ovarian hyperstimulation (COH) who responded with an increasing number of eggs compared with controls (51% and 39%, respectively). When analyzing samples from patients who responded with a low number of oocytes, no significant increase was observed.
CONCLUSIONS: It is known that in OHSS, the increase in capillary permeability is related to the administration of gonadotropins, and is believed to be mediated by a vasoactive substance of ovarian origin. In this study, FF and PF from patients undergoing COH showed a significant increase in the permeability rate through endothelial cells in vitro. Based on these findings, it could be hypothesized that if the same events took place in vivo, the isolation of this factor from ovarian source could be of significant importance to elucidate the pathogenesis of OHSS.

Entities:  

Mesh:

Year:  1995        PMID: 7843429     DOI: 10.1016/s0015-0282(16)57353-1

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  12 in total

1.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

2.  Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization.

Authors:  Stephen R Lincoln; Michael S Opsahl; Keith L Blauer; Susan H Black; Joseph D Schulman
Journal:  J Assist Reprod Genet       Date:  2002-04       Impact factor: 3.412

Review 3.  Ovarian hyperstimulation syndrome: pathophysiology and prevention.

Authors:  Carolina O Nastri; Rui A Ferriani; Isa A Rocha; Wellington P Martins
Journal:  J Assist Reprod Genet       Date:  2010-02-06       Impact factor: 3.412

4.  In controlled ovarian hyperstimulation, steroid production, oocyte retrieval, and pregnancy rate correlate with gene expression of vascular endothelial growth factor.

Authors:  N Doldi; M Bassan; F M Fusi; A Ferrari
Journal:  J Assist Reprod Genet       Date:  1997-11       Impact factor: 3.412

5.  A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome.

Authors:  S Ogawa; H Minakami; S Araki; T Ohno; M Motoyama; H Shibahara; I Sato
Journal:  J Assist Reprod Genet       Date:  2001-02       Impact factor: 3.412

6.  Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: "tap early and often" versus hospitalization.

Authors:  John M Csokmay; Belinda J Yauger; Melinda B Henne; Alicia Y Armstrong; John T Queenan; James H Segars
Journal:  Fertil Steril       Date:  2008-11-05       Impact factor: 7.329

7.  Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome.

Authors:  E R Levin; G F Rosen; D L Cassidenti; B Yee; D Meldrum; A Wisot; A Pedram
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

8.  Symptomatic hemorrhagic pleural effusion: A rare presentation of ovarian hyperstimulation syndrome: A Case Report.

Authors:  Ali Alaraj
Journal:  Int J Health Sci (Qassim)       Date:  2013-11

Review 9.  Prevention of Ovarian Hyperstimulation Syndrome: A Review.

Authors:  Vinayak Smith; Tiki Osianlis; Beverley Vollenhoven
Journal:  Obstet Gynecol Int       Date:  2015-05-14

10.  The influence of obesity on incidence of complications in patients hospitalized with ovarian hyperstimulation syndrome.

Authors:  Rachel S Mandelbaum; Liat Bainvoll; Caroline J Violette; Meghan B Smith; Shinya Matsuzaki; Maximilian Klar; Jacqueline R Ho; Kristin A Bendikson; Richard J Paulson; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2021-07-09       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.